Company intelligence / Profile preview
NextCell Pharma AB
Huddinge, Stockholm County, Swedennextcellpharma.com ↗
- Ownership
- Private
- Employees
- ~24
- Development stage
- Phase 2
01
Overview
ProTrans has demonstrated both safety and efficacy in Phase I and II clinical trials for type 1 diabetes, with a single infusion preserving endogenous insulin production for at least 3 years[9]. The therapy dampens destructive autoimmune effects and slows disease progression[5].
- Therapeutic areas
- EndocrinologyInfectious DiseasesImmunology
- Modalities
- Mesenchymal stromal cell therapiesStem cell therapies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
FamicordTx (8.5% ownership)
Beyond the preview
Go deeper on NextCell Pharma AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NextCell Pharma AB.